Market News AIOpen the app

Immuron has hired LifeSci Capital to help find ways to increase value for its shareholders.

MarketRead the original at globenewswire.com
Neutral

Immuron hired LifeSci Capital to examine possible deals and other options, but no transaction is assured. The review alone does not change the company's outlook.

IMRN · Immuron Limited

AI read · Neutral

The AI's read

The review could lead to a merger, licensing deal, or another change, but none has been announced. Immuron says it will keep working on its oral antibody platform. With no deal or business change confirmed, the news leaves its outlook unchanged.

Get alerts for IMRN

Follow Immuron Limited (IMRN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IMRN
Free on the App Store and Google Play, or on the web.